InsiderTradr

Dishman Carbogen Amcis Limited (DCAL.NS)

NSE · INR · Healthcare · Biotechnology

₹147.70 (+6.38%) as of

Key statistics

Market cap
23.16B
P/E (TTM)
146.24
Forward P/E
11.82
EPS (TTM)
1.01
Dividend yield
0.00%
52-week range
128.50 – 303.00
Beta
0.65
Revenue (TTM)
29.01B
Profit margin
0.56%
Volume
199.47k

About Dishman Carbogen Amcis Limited

Dishman Carbogen Amcis Limited provides contract development and manufacturing organization (CDMO) services for the pharmaceutical and healthcare industries worldwide. It operates through Integrated CDMO Platform and Marketable Molecules segments. The company offers cholesterol and vitamin D analogs; soft gel capsules and formulations; intermediate and active pharmaceutical ingredients (APIs) which cover specific therapeutic areas, such as anesthetics, and contrast media agents for diagnostics, ophthalmic treatments, laxatives, and organophosphate antidotes; ammonium and phosphonium; quats, phosphoranes, and wittig reagents; generic intermediates; cholesterol and lanolin-related products; sterile injectables; specialty chemicals and disinfectants, as well as hand and body wash, sanitizers, and antiseptic formulations. It also provides encapsulation and formulation capabilities; phase transfer catalysts; drug product, finished, and HiPo formulations; generic and highpotent APIs; Health and personal care solutions; and drug linkers and payloads. The company was founded in 1983 and is headquartered in Ahmedabad, India. Dishman Carbogen Amcis Limited is a subsidiary of Adimans Technologies LLP.

Sector
Healthcare
Industry
Biotechnology
Headquarters
Ahmedabad, India
Employees
934

imdcal.com

Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.

Related stocks